Free Trial

Novo Nordisk A/S (NYSE:NVO) Stock Price Down 4.2% - Here's What Happened

Novo Nordisk A/S logo with Medical background

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares were down 4.2% during mid-day trading on Friday . The stock traded as low as $100.81 and last traded at $100.93. Approximately 2,143,479 shares changed hands during trading, a decline of 52% from the average daily volume of 4,430,680 shares. The stock had previously closed at $105.32.

Analysts Set New Price Targets

Several analysts have recently issued reports on NVO shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $144.50.

Read Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

The firm has a 50 day moving average of $119.17 and a two-hundred day moving average of $129.75. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $457.28 billion, a P/E ratio of 32.66, a P/E/G ratio of 1.31 and a beta of 0.42.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVO. Kingsview Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 835.9% during the 1st quarter. Kingsview Wealth Management LLC now owns 21,208 shares of the company's stock worth $2,723,000 after acquiring an additional 18,942 shares during the period. Blair William & Co. IL boosted its holdings in Novo Nordisk A/S by 12.9% during the first quarter. Blair William & Co. IL now owns 71,036 shares of the company's stock valued at $9,121,000 after purchasing an additional 8,126 shares in the last quarter. Great Lakes Retirement Inc. bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $791,000. Nwam LLC raised its holdings in shares of Novo Nordisk A/S by 51.3% in the 1st quarter. Nwam LLC now owns 3,831 shares of the company's stock worth $488,000 after buying an additional 1,299 shares in the last quarter. Finally, First Foundation Advisors lifted its position in shares of Novo Nordisk A/S by 3.1% during the 1st quarter. First Foundation Advisors now owns 7,416 shares of the company's stock worth $952,000 after buying an additional 223 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Novo Nordisk A/S right now?

Before you consider Novo Nordisk A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.

While Novo Nordisk A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines